Heron flying on Phase IIb pain data ahead of NDA

Heron Therapeutics Inc. (NASDAQ:HRTX) added $9.25 (30%) to $39.95 on Thursday after reporting that HTX-011 met the primary endpoint in a pair of Phase IIb trials to treat postoperative pain. The stock move added more than $650 million to the company's market cap.

Heron intends to submit an NDA to FDA next half for the candidate. Also on Thursday, FDA granted breakthrough therapy designation to HTX-011...